Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2026
Pharma News, 2026
Vericel Wins FDA Approval For New MACI Cell Therapy Manufacturing Site
Vericel Corporation receives FDA approval for its new state-of-the-art cell therapy manufacturing facility in Burlington, MA to expand MACI production.
HotSpot Therapeutics Presents Preclinical Data on IRF5 Lupus Inhibitors
HotSpot Therapeutics presents preclinical data for its small molecule IRF5 inhibitor program for systemic lupus at the 15th European Lupus Meeting.
Propanc's PRP Shows >85% Tumor Growth Inhibition in Pancreatic Cancer
Propanc Biopharma's lead asset PRP shows over 85% tumor growth inhibition in preclinical pancreatic models, offering a promising new metastasis treatment.
Novo Nordisk Starts €432m Ireland Facility Upgrade for Oral Wegovy Pills
Novo Nordisk invests €432m to upgrade its Ireland facility, boosting oral Wegovy (semaglutide) production to meet surging global weight loss drug demand.
NATCO Pharma Launches Generic Blood Cancer Drug Pomalidomide in the US
NATCO Pharma, partnering with Breckenridge Pharmaceutical, launches generic Pomalidomide capsules in the US, offering affordable blood cancer treatment.
Roche's Phase III Trial of Fenebrutinib in RMS Meets Primary Endpoint
Roche reports its Phase III FENhance 1 trial for fenebrutinib in relapsing multiple sclerosis met its primary endpoint, reducing relapse rates by 51%.
Engineered Immune Cells (CARMA) Show Promise Against Brain Metastases
New preclinical study shows engineered CAR macrophages (CARMA) can cross the blood-brain barrier and effectively attack lung cancer brain metastases.
FDA Approves Eton's Desmoda Oral Solution for Central Diabetes Insipidus
The FDA has approved Desmoda (desmopressin acetate) oral solution by Eton Pharmaceuticals for managing central diabetes insipidus in adults and children.
Asahi Kasei Acquires Aicuris Anti-infective Cures for $920.7 Million
Asahi Kasei is acquiring Aicuris Anti-infective Cures for $920.7m to expand its specialty pharma platform into severe infectious diseases and boost R&D.
FDA Unveils Ultra-Rare Therapy Pathway & Fast-Tracks New Lung Cancer Drug
The FDA released draft guidance for an ultra-rare disease therapy pathway, the Plausible Mechanism Framework, and fast-tracked lung cancer drug Hernexeos.
Quotient & Ipsen Extend Partnership for Ultra-Rare FOP Disease Therapy
Quotient Sciences and Ipsen extend their commercial partnership to produce Sohonos for FOP, enhancing HPAPI capabilities at the Boothwyn, PA facility.
India's Single-Dose Dengue Vaccine Candidate Advancing to Phase 3 Trials
Panacea Biotec's single-dose dengue vaccine candidate, DengiAll, advances to Phase III trials, offering hope for India's first domestic dengue prevention.
1
2
3
4
5
6
7
8
9
